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Recurrent mutations in cohesin complex proteins
have been identified in pre-leukemic hematopoietic
stem cells and during the early development of acute
myeloid leukemia and other myeloid malignancies.
Although cohesins are involved in chromosome sep-
aration and DNA damage repair, cohesin complex
functions during hematopoiesis and leukemic devel-
opment are unclear. Here, we show that mutant
cohesin proteins block differentiation of human
hematopoietic stem and progenitor cells (HSPCs)
in vitro and in vivo and enforce stem cell programs.
These effects are restricted to immature HSPC pop-
ulations, where cohesin mutants show increased
chromatin accessibility and likelihood of transcrip-
tion factor binding site occupancy by HSPC reg-
ulators including ERG, GATA2, and RUNX1, as
measured by ATAC-seq and ChIP-seq. Epistasis ex-
periments show that silencing these transcription
factors rescues the differentiation block caused by
cohesin mutants. Together, these results show that
mutant cohesins impair HSPC differentiation by
controlling chromatin accessibility and transcription
factor activity, possibly contributing to leukemic
disease.
INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive malignancy
of the bone marrow characterized by expansion of immature
myeloid cells defective in their maturation and function (Estey
and Do¨hner, 2006; Lo¨wenberg et al., 1999). Large-scale AML
genome re-sequencing efforts have identified novel recurrently
mutated genes, including the members of the cohesin complex
(RAD21, SMC3, SMC1A, and STAG2), implicated in the patho-
genesis of this disease (Cancer Genome Atlas ResearchCellNetwork, 2013). The manner in which multiple mutations accu-
mulate in a single lineage of cells has been an area of intense
investigation.
Over the last decades, a number of studies from many inves-
tigators have led to a model in which leukemic mutations serially
accumulate in clones of self-renewing hematopoietic stem cells
(HSCs) (reviewed in Corces-Zimmerman and Majeti, 2014; Jan
and Majeti, 2013), and we provided evidence supporting this
model through the identification of residual HSCs from the time
of AML diagnosis harboring some, but not all, of the mutations
in the patient-matched leukemia cells (Jan et al., 2012). We
termed these cells pre-leukemic HSCs and further demonstrated
the serial accumulation of pre-leukemic mutations in single cells
as hypothesized. Subsequent analysis of a larger cohort of pa-
tients demonstrated that pre-leukemic mutations preferentially
occur in genes involved in the regulation of the epigenome,
including cohesin (Corces-Zimmerman et al., 2014).
Recurrent mutations in cohesin have been identified in myelo-
dysplastic syndrome (MDS), AML, and other myeloid malig-
nancies (Leeke et al., 2014). Cohesin mutations are almost
always mutually exclusive, suggesting that an alteration in one
component may be sufficient to affect the entire complex, and
they collectively occur in approximately 15% of AML cases
and other myeloid malignancies (Kon et al., 2013; Cancer
Genome Atlas Research Network, 2013).
The cohesin complex functions to hold chromatin strands
within a ring-like structure composed of the four core compo-
nents (Diaz-Martinez and Clarke, 2009). Although its best-estab-
lished role is to maintain the polarity of sister chromatids during
mitosis, cohesin is also involved in double-stranded DNA dam-
age repair and regulation of transcription through transcription
factor (TF) recruitment and its interaction with CTCF (Panigrahi
and Pati, 2012). The discovery of recurrent mutations in the
cohesin complex indicates another pathway that is relevant for
AML, yet the manner in which they contribute to pathogenesis
has not been defined. Here, we build on the observation that
cohesin mutations are often seen as early, founder mutations
in pre-leukemic HSCs (Corces-Zimmerman et al., 2014) and
investigated their effects on differentiation and self-renewal of
human hematopoietic stem and progenitor cells (HSPCs).Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Inc. 675
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Figure 1. Cohesin Mutants Impair Hematopoietic Differentiation
(A) Schematic diagram of the cohesin complexwith four components (RAD21, SMC1A, SMC3, and STAG2). Mutations found in AML (in the Cancer GenomeAtlas
Research Network or our own tissue bank) in each cohesin component are indicated by triangles. Specificmutations used for studies reported here are indicated.
(*) indicates nonsense mutations.
(B) TF-1 cells were infected with lentiviruses encoding doxycycline (DOX)-inducible cohesin WT or mutant variants and GFP. Erythroid differentiation of parental
TF-1 cells and variants was determined by flow cytometry for GPA expression after 2 initial days of DOX treatment and 8 days of EPO andDOX treatment. Relative
expression is shown as mean fluorescence intensity (MFI) of GPA normalized to IgG isotype control. **p < 0.01.
(C) Expression of fetal hemoglobin was determined by qRT-PCR for cells treated as in (B). Values are normalized to No DOX controls. **p < 0.01.
(D) Expression of KLF-1 was determined by qRT-PCR for cells treated as in (B). Values are normalized to No DOX controls. **p < 0.01.
(E) TF-1 cells were treated as in (B) and then washed out of DOX and maintained in EPO media for an additional 4 days. Erythroid differentiation of parental TF-1
cells and variants was determined by flow cytometry for GPA expression. Relative expression is shown as MFI of GPA normalized to IgG isotype control. No
statistically significant differences were detected.
(F) Expression of fetal hemoglobin was determined by qRT-PCR for cells treated as in (E). Values are normalized to TF-1 control. No statistically significant
differences were detected.
(G) Expression of KLF-1 was determined by qRT-PCR for cells treated as in (E). Values are normalized to TF-1 control. No statistically significant differences were
detected.RESULTS
Cohesin Mutants Impair Hematopoietic Differentiation
Mutations in cohesin complex genes associated with myeloid
malignancies are usually heterozygous and include both
missense and nonsense mutations distributed throughout their676 Cell Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Incoding regions (Figure 1A), suggesting that these mutations
result in haploinsufficiency and/or the generation of dominant-
negative mutant proteins that disrupt cohesin functions (Kon
et al., 2013). Thus, in order to investigate the effects of cohesin
mutations on hematopoiesis, we engineered human AML cell
lines (verified to lack endogenous mutations in all cohesinc.
components) to express WT or mutant cohesin components
under the control of a doxycycline (DOX)-inducible promoter
(Figures S1A and S1B). We investigated multiple mutations
(Figure 1A) identified in primary AML samples from our own lab-
oratory or in the Cancer Genome Atlas Research Network
cohort, including both missense and nonsense mutations in all
four core cohesin components (RAD21 E212*, RAD21 Q592*,
SMC1A R711G, SMC3 G662C, and STAG2 Q801*, where [*] in-
dicates a stop codon).
Cohesin mutants were initially investigated in the TF-1 erythro-
leukemia cell line due to its ability to undergo partial erythroid dif-
ferentiation in response to erythropoietin (EPO). Upon exposure
to EPO for 6 days, cohesion-mutant-induced cell lines exhibited
a significant decrease in erythroid differentiation as determined
by surface expression of glycophorin A (GPA) (Figure 1B) and
RNA expression of fetal hemoglobin (HGB1/2) (Figure 1C) and
KLF-1 (Figure 1D), a key erythroid TF. This suggests that cohesin
mutants can act in a dominant-negative manner to impair
hematopoietic differentiation. This phenotype was supported
by expression of WT and mutant cohesin components in the
THP-1 AML cell line, which can undergo myeloid differentiation
upon addition of all-trans retinoic acid (ATRA) or phorbol 12-myr-
istate 13-acetate (PMA). Upon exposure to these agents, cohe-
sion-mutant-induced cell lines exhibited significantly decreased
surface expression of the mature myeloid marker CD11b
compared to WT or parental THP-1 cells (Figures S1C and S1D).
Although previously published reports (Kon et al., 2013)
showed an effect of cohesin mutants on cell proliferation, we
saw no significant changes in either proliferation (Figure S1E)
or cell death (Figure S1F). Furthermore, given the role of cohesin
in double-stranded DNA damage repair, we determined expres-
sion of phospho-gamma H2AX, a marker of DNA double-strand
breaks. Even after 18 days of cohesin mutant expression, there
were no changes in DNA damage compared to WT cells (Fig-
ure S1G), consistent with the finding that the majority of cohesin
mutant AML cases are of normal karyotype (Cancer Genome
Atlas Research Network, 2013).
To determine whether this impaired differentiation phenotype
was dependent on continuous expression of cohesin mutants,
TF-1 cells initially DOX-induced for 6 days in the presence of
EPO were removed from DOX and replated in EPO-containing
medium. Analysis 4 days later showed a strong induction of
erythroid markers in all mutant cell lines (Figures 1E–1G), indi-
cating that the impairment of differentiation is reversible in this
model.
Cohesin Mutants Impair Myeloid, Erythroid, and Stem
Cell Differentiation of Primary Human HSPCs
These cell line assays support the hypothesis that cohesin
mutations contribute to disease pathogenesis by impairing he-
matopoietic differentiation in HSPCs. To directly investigate
this hypothesis, we transduced CD34-enriched primary normal
human cord blood cells with lentivirus encoding constitutive
expression of either WT or mutant cohesin components with a
GFP marker (Figure S2A). Transduced GFP+ cells were purified
by fluorescence activated cell sorting (FACS) and cultured
under several conditions (Figure 2A). First, cells were cultured
with cytokines designed to promote retention of HSPCs (Chan
et al., 2015), and these cultures showed a significantlyCellincreased frequency of CD34-expressing cells compared to
WT or empty vector controls (Figures 2B and 2C). Second, cells
were cultured under conditions designed to promote myeloid
differentiation (Sinha et al., 2015), and resulting cultures showed
a significant decrease in CD14-expressing cells compared to
controls (Figures 2D and 2E). Third, cells were cultured under
conditions designed to promote erythroid differentiation, and
cohesin mutant cultures showed a significant decrease in
CD71 and GPA-double-positive erythroid cells (Figures 2F and
2G). As with the cell lines, expression of cohesin mutants did
not affect cord blood cell proliferation or cell death (Figures
S2B and S2C). No impaired differentiation was observed with
FACS-purified GFP cells from the same normal donors in
these assays (Figures S2D–S2F). Together, these data suggest
that cohesin mutations impart a differentiation block on primary
human HSPCs.
Knockdown of RAD21 Impairs Hematopoietic
Differentiation In Vitro and In Vivo
In addition to acting in a dominant-negative manner, cohesin
mutations may also act through loss of function. To investigate
this mechanism, we used a second model system in which
we knocked down the expression of RAD21 using shRNA-en-
coding lentiviruses. We engineered inducible shRNA vectors
containing one of three independent validated RAD21 targeting
sequences, and separately, two constitutive RAD21-shRNA
targeting vectors, to silence RAD21 in TF-1 cells and CD34-
enriched cord blood cells. Both constitutive and inducible
shRNA-mediated knockdown led to a reduction in RAD21
expression by 80%–90% in CD34+ cord blood cells (Fig-
ure S3A) and strong protein knockdown in TF-1 cells (Fig-
ure S3B). When cultured with EPO, the RAD21-knockdown
TF-1 cells showed a marked reduction in erythroid differentia-
tion as measured by expression of HGB1/2 and KLF-1 (Figures
S3C and S3D). Moreover, constitutive RAD21-knockdown in
cord blood HSPCs followed by culture in the HSPC-retention
medium resulted in a significantly increased frequency of
CD34-expressing cells compared to control (Figures S3E and
S3F). Similar to the results with cohesin mutants, knockdown
of RAD21 in HSPCs showed a marked decrease in CD14-
expressing cells in the myeloid culture medium (Figures S3G
and S3H) and a significant decrease in CD71 and GPA-dou-
ble-positive erythroid cells in the erythroid culture medium (Fig-
ures S3I and S3J).
Finally, we investigated the effects of RAD21-knockdown on
human HSPC engraftment and differentiation in vivo in NOD/
SCID/IL2R-gamma null (NSG) mice. CD34-enriched cord blood
cells were transduced with lentivirus encoding for constitutive
RAD21-shRNA knockdown and then transplanted into NSG
mice. After 7 weeks, there were no statistically significant differ-
ences in human hematopoietic engraftment levels between
scrambled shRNA control and RAD21-shRNAs (Figure 3A).
However, there was a significant increase in human CD34-ex-
pressing cells in the bonemarrow (Figures 3B and 3C), indicating
that cohesin mutants can impair hematopoietic differentiation
in vivo. Furthermore, flow cytometry analysis of the engrafted
human cells showed a significant increase in CD33+ myeloid
cells compared to CD19+CD20+ B-lymphoid cells, indicating a
skewing toward the myeloid lineage (Figures 3D and 3E). ThisStem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Inc. 677
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Figure 2. Cohesin Mutants Impair Myeloid,
Erythroid, and Stem Cell Differentiation of
Primary Human HSPCs
(A) Schematic of in vitro differentiation experiments
using human CD34-enriched HSPCs from cord
blood.
(B) HSPCs were infected with lentiviruses encoding
GFP alone (control) or GFP in addition to the indi-
cated cohesin variants. 72 hr post-infection, GFP+
cells were isolated by FACS and cultured in HSPC-
retention medium. 6 days later, cells were analyzed
for expression of progenitor markers CD34 and
CD38. Representative FACS plots are shown.
(C) Summary of data from three independent ex-
periments as described in (B); the percentage of
CD34+ cells was normalized to GFP control.
Unpaired Student’s t test was used to determine
statistical significance between WT and mutant
populations. **p < 0.01.
(D) HSPCs isolated and lentivirally transduced as
in (B) were cultured in myeloid differentiation
medium. 6 days later, cells were analyzed for
expression of myeloid markers CD33 and CD14.
Representative FACS plots are shown.
(E) Summary of data from three independent ex-
periments as described in (D); the percentage
of CD33+/CD14+ cells was normalized to GFP
control. Unpaired Student’s t test was used to
determine statistical significance between WT and
mutant populations. **p < 0.01.
(F) HSPCs isolated and lentivirally transduced
as in (B) were cultured in erythroid differentiation
medium. 6 days later, cells were analyzed for
expression of erythroid markers CD71 and GPA.
Representative FACS plots are shown.
(G) Summary of data from three independent ex-
periments as described in (F); the percentage of
GPA+/CD71+ cells was normalized to GFP control.
Unpaired Student’s t test was used to determine
statistical significance between WT and mutant
populations. **p < 0.01.phenotype is consistent with the association of cohesin muta-
tions with human myeloid malignancies.
Thus, as with overexpression of cohesin mutants, decreased
expression of cohesin results in impaired hematopoietic differen-
tiation, suggesting that these mutations can act through both
haploinsufficiency and dominant-negativemechanisms.We per-
formed whole-cell western blots on primary AML samples (Table
S1) with either WT or mutant cohesin to determine cohesin
component protein levels. In samples that were mutated for a
member of the cohesin complex, we detected a slight reduction
in the protein level of that component compared to WT samples,
and in some cases, a reduction of its binding partners (Fig-
ure S4A). Next, we investigated formation of the cohesin protein
complex in WT and mutant primary AML cells using co-immuno-
precipitation. Cellular lysates were immunoprecipitated with an
antibody to SMC1A and then blotted for protein levels of
RAD21 and SMC3. The results indicated varying levels of protein678 Cell Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Inc.complex formation, although in one of the
samples (SU067, Q592*) that had a trun-
cation in RAD21 at the SMC1A-interactingC terminus, no RAD21 was co-immunoprecipitated, indicating
that in some cases, cohesin mutations have a dominant-nega-
tive effect in abrogating complex formation (Figure S4B).
Cohesin Mutants Induce Myeloid Skewing and
Increased Serial Replating of Human HSPCs In Vitro
Next, we investigated the effect of mutant cohesin on human
HSPC colony formation and serial replating capacity. Cord blood
cells transduced with cohesin WT, mutant, or control lentivirus
were plated in methylcellulose for 14 days. No significant differ-
ences in the number of colonies were observed after the first
plating (Figure 4A); however, an increase in CFU-GM myeloid
colonies was detected with expression of the cohesin mutants
(Figure 4B). Flow cytometry analysis of the resulting cells demon-
strated a statistically significant increase in CD33+ myeloid cells
compared to GPA+ erythroid cells in cohesin mutant colonies,
indicating a skewing of differentiation to the myeloid lineage
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Figure 3. Knockdown of RAD21 Impairs
Hematopoietic Differentiation and Induces
Myeloid Skewing In Vivo
(A) Human CD34-enriched cord blood HSPCs
were infected with constitutive RAD21 shRNA or
scramble control RFP-encoding lentiviral vectors.
72 hr post-infection 50,000 cells were trans-
planted by intrafemoral injection into NSG mice
(three mice per condition). 7 weeks post-trans-
plant, bone marrow aspirates were analyzed for
human engraftment (human CD45+) and RFP+
expression. No statistically significant differences
were detected.
(B) Human RFP+ engrafted cells from (A) were
analyzed for expression of progenitor markers
CD34 and CD38. Representative FACS plots are
shown.
(C) Summary of data from 3 independent experi-
ments as described in (B); the percentage of
CD34+ cells was normalized to non-transduced
control. Unpaired Student’s t test was used
to determine statistical significance between
scramble shRNA and RAD21 shRNA populations.
**p < 0.01.
(D) Human RFP+ engrafted cells from (A) were
analyzed for expression of B lymphoid (CD19 &
CD20) and myeloid markers (CD33). Representa-
tive FACS plots are shown.
(E) Summary of data from three independent ex-
periments as described in (D). The percentage of
CD33+ cells is shown. Unpaired Student’s t test
was used to determine statistical significance
between non-transduced and scramble shRNA
versus RAD21 shRNA populations. **p < 0.01.(Figure 4C). Upon replating, cohesin mutant cells retained the
ability to serially generate colonies through the fifth replating,
while essentially no WT or control colonies were detected after
the second plating (Figure 4A). This increased serial-replating
capacity suggests that mutant cohesin enforces stem cell func-
tions in human HSPCs.
Cohesin Mutants Enforce Expression of Hematopoietic
and Leukemia Stem Cell Gene Expression Programs
To further investigate the effect of mutant cohesin on stem cell
programs in human HSPCs, we conducted global transcriptional
profiling by microarray analysis of cord blood cells transduced
with cohesin WT, mutant, or control lentiviral vectors. Using
stringent bioinformatic criteria of fold change > 3 and FDR <
0.05, 202 unique genes differentially expressed between cohesin
mutant and control HSPCs (94 upregulated and 108 downregu-
lated; Table S2) were identified. Based on hierarchical clusteringCell Stem Cell 17, 675–688,by Pearson correlation, the mutant sam-
ples formed a distinct cluster from WT
and control samples (Figure 4D). In the
genes upregulated in cohesion-mutant-
transduced cord blood, there was a
strong enrichment for gene sets highly ex-
pressed in normal cord blood HSCs and
curated gene sets defining AML stem
cell signatures (Eppert et al., 2011; Gen-tles et al., 2010) (Figure 4E). Genes upregulated at least 3-fold
in cohesin mutant samples included many known to be crucial
for HSC function, such as homeobox genes (Spencer et al.,
2015) andMEIS1 (Wilson et al., 2010) (Table S2). Conversely, co-
hesin mutant samples exhibited lower expression of gene sets
and genes that are crucial for myeloid differentiation such as
myeloperoxidase (MPO) and colony stimulating factor 1 receptor
(CSF1R) (Figure 4F). The enrichment for expression of HSC and
AML leukemia stem cell gene sets supports themodel that cohe-
sin mutants enforce stem cell programs in human HSPCs.
Cohesin Mutants Impair Human HSPC Differentiation in
a Cell-Context-Dependent Manner
Cohesin mutations were identified in pre-leukemic HSCs in
several of the cases we investigated (Corces-Zimmerman
et al., 2014; Jan et al., 2012), suggesting that they may act
to impair hematopoietic differentiation and enforce stem cellDecember 3, 2015 ª2015 Elsevier Inc. 679
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Figure 4. Cohesin Mutants Induce Myeloid
Skewing, Increase Serial Replating, and
Enforce Stem Cell Gene Expression Pro-
grams in Human HSPCs
(A) Human CD34-enriched HSPCs were infected
with lentiviruses encoding GFP alone (control) or
GFP in addition to the indicated cohesin variants.
72 hr post-infection, GFP+ cells were isolated by
FACS and cultured in methylcellulose for colony-
forming assays. Every 14 days, colonies were
scored for morphology and cells (1,000–10,000)
were replated up to five cycles. The number of
colonies per 1,000 cells in the first plating is indi-
cated on the left; the right indicates the number of
colonies per 1,000 cells in the subsequent plat-
ings. nd, none detected. Unpaired Student’s t test
was used to determine statistical significance
between WT and mutant populations. *p < 0.05
and **p < 0.01.
(B) The morphological colony-types from the
primary plating of cells as described in (A) are
indicated. Statistically significant differences in the
percent of CFU-GM were detected. **p < 0.01.
(C) Cells from the methylcellulose colonies from
(B) were isolated and analyzed for expression of
myeloid marker (CD33) or erythroid marker (GPA).
Representative FACS plots are shown. Data are
representative of three independent experiments.
(D) Human CD34-enriched HSPCs were infected
with control, cohesin WT, or cohesin mutant
GFP-encoding lentiviruses. 72 hr later, GFP+
transduced cells were FACS purified and
subject to gene expression analysis on Affymetrix
microarrays. The resulting expression data was
analyzed by unsupervised hierarchical clustering
and the Pearson correlation dendogram is shown
here.
(E) Gene expression microarray data as described
in (D) was utilized in Gene Set Enrichment Analysis
(GSEA) to identify gene sets enriched in cohesin
mutant compared to cohesin WT and control
samples in both the molecular signatures data-
base (MSigDB) and manually curated leukemia
stem cell gene sets.
(F) GSEA identified gene sets enriched in WT and
control samples compared to cohesin mutants in
the MSigDB.programs in a cell-context-dependent manner. To investigate
this hypothesis, six human HSPC subpopulations were isolated
from human cord blood by FACS: HSCs, multipotent progenitors
(MPPs), lymphoid-primed multipotent progenitors (LMPPs),
common myeloid progenitors (CMPs), megakaryocyte-erythroid
progenitors (MEPs), and granulocyte-monocyte progenitors
(GMPs) (Goardon et al., 2011; Majeti et al., 2007) (Figure S5A).
These cells were then transduced with cohesin WT, mutant, or
control lentivirus and cultured in either the myeloid-differentia-
tion promoting or erythroid-differentiation promoting conditions.
Strikingly, a strong myeloid differentiation block was only
observed with cohesion-mutant-transduced HSCs and MPPs,
and to a lesser extent CMPs (Figures 5A and 5B). Similar results
were observed in the erythroid assay (Figures 5C and 5D).
Parallel studies with RAD21 shRNA-mediated knockdown also
showed differentiation defects only in the most immature popu-
lations (Figures 5B and 5D, Figures S5B and S5C). Notably,680 Cell Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Incohesion-mutant-transduced and cohesin-deficient GMPs and
MEPs showed no differentiation block in the myeloid and
erythroid assays, respectively, indicating that the effect of
mutant cohesin is context dependent and restricted to the
most immature human HSPCs.
Cohesin Mutants Alter Chromatin Accessibility at
Transcriptional Regulatory Elements
Cohesin functions to establish and maintain DNA accessibility,
and knockdown of cohesin can lead to a decrease in chromatin
accessibility at TF clustered regions (Yan et al., 2013), leading us
to hypothesize that cohesin mutants impart their phenotypic
effects through modulation of chromatin accessibility. To inves-
tigate this hypothesis, we employed a recently described tech-
nique known as the assay for transposase-accessible chromatin
followed by sequencing (ATAC-seq) (Buenrostro et al., 2013) to
assess the genome-wide accessibility to the Tn5 transposase.c.
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Figure 5. Cohesin Mutants Impair Human
HSPC Differentiation in a Cell-Context-
Dependent Manner
(A) Human CD34-enriched cord blood was sorted
for HSPC subpopulations (HSCs, MPPs, LMPPs,
CMPs, MEPs, and GMPs) (See Figure S5 for
sorting strategy). Each subpopulation was then
infected with lentiviruses encoding GFP alone
(control) or GFP in addition to the indicated co-
hesin variants. The virally transduced cells were
cultured in myeloid differentiation medium, as in
Figure 2. 8 days later, the cells were analyzed by
flow cytometry for expression of myeloid markers
CD33 and CD14. Representative FACS plots of
GFP+ cells are shown.
(B) Summary of data from three independent ex-
periments as described in (A); the percentage of
CD14+ cells was normalized to GFP control.
Scramble shRNA and RAD21 shRNA transduced
HSPC subpopulations (Figure S5B) are included in
the summary. Unpaired Student’s t test was used
to determine statistical significance between WT
and mutant populations. *p < 0.05 and **p < 0.01.
(C) HSPC subpopulations isolated and lentivirally
transduced as in (A) were cultured in erythroid
differentiation medium, as in Figure 2. 8 days later,
the cells were analyzed for expression of erythroid
markers CD71 and GPA. Representative FACS
plots of GFP+ cells are shown.
(D) Summary of data from three independent
experiments as described in (C); the percentage
of CD71+ cells was normalized to GFP control.
Scramble shRNA and RAD21 shRNA transduced
HSPC subpopulations (Figure S5C) are included in
the summary. Unpaired Student’s t test was used
to determine statistical significance between co-
hesin WT and mutant populations. **p < 0.01.Both cohesin WT and mutant-expressing TF-1 cell lines (RAD21
Q592* and RAD21 WT) and primary human cord blood trans-
duced with cohesin WT or mutant lentivirus were subject to
ATAC-seq. Two biological replicates in both cohesin WT and
mutant variantswere highly correlated to each other (FigureS6A),
indicating strong reproducibility of this technique on isolated
cord blood cells.
To determine whether cohesin mutants had an effect on chro-
matin accessibility, we first performed an unbiased analysis of
ATAC-seq signal intensity near transcription start sites (TSSs)
using all unique-mapped and properly paired ATAC-seq tags.
A decrease of the average intensity of ATAC-seq signal was
observed in RAD21 and SMC1A mutants (Figure 6A left panel)
and was further supported by less intensity over all TSS regions
in the cohesin mutant compared to WT samples (Figure 6A right
panel). Next, we further examined the nucleosome positioning
status surrounding the TSSs using a V-plot analysis (Figure 6B).
In this approach, the mid-points of all fragments were centered
on the x axis relative to TSSs, and fragment sizes were arrangedCell Stem Cell 17, 675–688,from the smallest to the largest on the
y axis. In the cohesin WT, nucleosome
positioning leads to a pattern of enriched
nucleosome-free fragments (<100 bp)
and mono-nucleosome fragments (180–247 bp) surrounding TSSs (Figure 6B). However, the enrichment
of nucleosome-free and mono-nucleosome fragments (‘‘open-
chromatin’’ indicators) was remarkably reduced in the cohesin
mutants (Figure 6B), suggesting that appropriate nucleosome
positioning with an open-chromatin status around TSSs was dis-
rupted due to mutant RAD21 and SMC1A. In addition to the
chromatin accessibility near TSSs, we further investigated chro-
matin accessibility globally using a functional genomic annota-
tion based on 15 chromHMM states (Ernst and Kellis, 2012)
derived from ENCODE histone markers on the K562 chronic
myeloid leukemia cell line. The cohesin mutants exhibited less
accessibility in active transcription regions, such as promoters
and enhancers, as well as in insulator sites where CTCF is bound
(Figure S6B).
Cohesin Mutants Exhibit Enrichment for Accessible
HSPC TF Motifs
While cohesin mutants exhibited global reduced chromatin
accessibility at transcriptional regulatory elements, increasedDecember 3, 2015 ª2015 Elsevier Inc. 681
(legend on next page)
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accessibility was detected at some sites. To characterize chro-
matin regions with differential accessibility in cohesin WT and
cohesion-mutant-expressing cells, we performed motif search-
ing of the gained and lost open accessible peaks with cohesin
disruption (1,940 gained peaks and 1,551 lost peaks in RAD21
mutant; 5,230 gained peaks and 4,662 lost peaks in SMC1Amu-
tants; p < 0.01 and fold change > 2). Motif analysis of more highly
accessible sites in cohesin mutant samples identified a strong
enrichment for TF binding sites including ERG, GATA2, and
RUNX1, which are known to be highly expressed and critical reg-
ulators of HSPCs (Wilson et al., 2010) (Figure 6C and Table S3).
RNA expression analysis using qRT-PCR demonstrated that
cohesion-mutant-transduced cells exhibited increased expres-
sion of these three TFs compared to WT controls and did so at
levels similar to those of immature CD34+CD38 cells freshly
isolated from cord blood (Figure S6C). For instance at the
CD34 locus, the CD34 promoter and upstream enhancer show
higher accessibility in RAD21 mutant cells compared to WT;
this enhancer is known to be bound by GATA2 in K562 cells (Fig-
ure 6D). Collectively, these results support a model in which
mutant cohesin impairs hematopoietic differentiation and en-
forces stem cell programs through the modulation of TF chro-
matin accessibility.
CohesinMutants Exhibit IncreasedOccupancy of Select
HSPC TFs
To corroborate whether increased accessibility at ERG, GATA2,
and RUNX1 motifs indicated a higher likelihood of binding of
these TFs, we performed footprinting analysis using protein
interaction quantification (PIQ) software (Sherwood et al.,
2014). The output of PIQ is the probability of occupancy for
each candidate-binding site in the genome. PIQ analysis re-
vealed a statistically significant increase in inferred binding for
ERG, GATA2, and RUNX1 in RAD21 mutant cells compared to
WT (Figure 6E), indicating that these TFs may be playing a signif-
icant role in enforcing stem cell programs in cohesin mutants.
To conclusively determine if there was increased binding of
these TFs in the presence of mutant cohesin, we conducted
ChIP-seq of GATA2 and RUNX1 in the TF-1 cells expressing
RAD21 Q592* or RAD21WT. After we normalized for sequencing
depth, this analysis showed that both TFs had a stronger signalFigure 6. Cohesin Mutants Exhibit Altered Chromatin Accessibility at T
Binding at HSPC TF Motifs
(A) Human CD34-enriched HSPCs were infected with lentiviruses encoding cohe
FACS and subject to ATAC-seq. Average diagram of genome-wide chromatin acc
SMC1A WT) and cohesin mutants (RAD21 mutant and SMC1A mutant) (left pan
window) in cohesin WT and mutants (right panel) is also shown.
(B) V-plot analysis of ATAC-seq fragments near TSSs (1 kbwindow) in cohesinWT
mutant). The x axis represents the distance between the centers of the fragments
0 to 9) represents the intensity of the ATAC-seq signal at the coordinate of this x
(C) Enrichment of TF motifs in the peaks that gain open accessibility in RAD21 m
blood cells (middle panel), and SMC1A mutant-expressing CD34+ cord blood ce
sorted from largest to smallest. The x axis is the sorted motif rank. The ETS, GA
(D) Illustrative UCSC genome browser track of normalized ATAC-seq signal at
overlayed, as well as K562 ChromHMM indicating a higher signal at an active pr
(E) PIQ footprinting analysis for ERG, GATA2, and RUNX1 indicates a higher lik
****p < 0.0001.
(F) TF-1 RAD21WT and RAD21 Q592* were induced with DOX for 6 days and then
signal (values normalized to input control) at GATA2 and RUNX1motif are shown h
indicates all GATA2 motifs in ATAC-seq peaks (from above).
Cellacross GATA2 or RUNX1 motif instances genome-wide in
RAD21 mutant cells compared to WT (Figure 6F). In addition,
GATA2 andRUNX1 occupancywas enriched at ATAC-seq peaks
identified in HSPCs (Figure 6F) and further enriched at ATAC-seq
peaks upregulated in RAD21 mutant HSPCs (Figure S6D). More-
over, genes known to be involved in hematopoietic stem cells
(TAL1, CD34, and GATA2) showed stronger binding of GATA2
and RUNX1 (see Figure S6E for illustrative tracks). Consistent
with these results, both GATA2 and RUNX1 exhibited increased
occupancy at chromatin accessible sites that were selectively
gained in TF-1 cells expressing RAD21 mutants compared to
RAD21 WT (Figure S6F). Moreover, SMC3 ChIP-seq revealed
loss of SMC3 occupancy in TF-1 cells expressing RAD21 Q592*
compared to cells expressing RAD21 WT. (Figure S6F). Thus,
both ATAC-seq and ChIP-seq directly demonstrate that mutant
cohesin subunits act as dominant negatives and alter chromatin
accessibility, leading to increased occupancy of HSPC TFs.
Cohesin-Mutant-Induced Stem Cell Programs Are
Dependent on ERG, GATA2, and RUNX1
Based on this model in which the effects of mutant cohesin are
mediated by TFs exhibiting increased chromatin accessibility
and binding such as ERG, GATA2, and RUNX1, we hypothesized
that knockdown of these TFs would prevent the maintenance in
CD34 expression observed in the in vitro HSPC retention assay
(Figure 2A). Two separate shRNA lentiviral constructs targeting
these TFs were validated for their knockdown effects in
FACS-purified transduced CD34+ cord blood cells (Figure 7A).
GATA1 and PU.1 were also targeted as control TFs expressed
in HSPCs and not demonstrating increased chromatin accessi-
bility in the ATAC-seq assays. We first confirmed TF knockdown
effects, demonstrating impaired erythroid differentiation with
knockdown of GATA1, while ERG, PU.1, and RUNX1 deficiency
significantly reduced myeloid differentiation in in vitro culture as-
says (Figures S7A–S7C). CD34+ cord blood cells were then
transduced with single or combination lentiviral vectors encod-
ing a cohesin WT or mutant component (GFP+) and a TF-target-
ing shRNA (RFP+) (Figure 7B). As expected, expression of cohe-
sin mutants with a scramble shRNA resulted in an increase in
CD34-expressing cells; however, knockdown of ERG, GATA2,
or RUNX1, but not GATA1 or PU.1, in the context of cohesinranscriptional Regulatory Elements, but Increased Accessibility and
sin WT or mutants in addition to GFP. 72 hr later, GFP+ cells were isolated by
essibility at TSS regions (2 kb window) comparing cohesin WT (RAD21WT and
el) is shown. Heat map of ATAC-seq signal intensity at all TSS regions (2 kb
(RAD21WT and SMC1AWT) and cohesin mutants (RAD21mutant and SMC1A
to the TSSs. The y axis represents the fragment length. The color (scaled from
y plane.
utant-expressing TF1 cells (left panel), RAD21 mutant-expressing CD34+ cord
lls (right panel). The y axis is –log10(p value) of a motif enrichment test, which is
TA, and Runt families are indicated by green, red, and blue, respectively.
the CD34 locus. K562 ENCODE ChIP-seq data for GATA2 and RAD21 are
omoter and strong enhancer of CD34.
elihood of TF occupancy in RAD21 mutant HSPCs compared to RAD21 WT.
subjected to ChIP-seq for GATA2 and RUNX1. Average diagrams for ChIP-seq
ere. The top row indicates all genome-wide GATA2motifs, and the bottom row
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Figure 7. Cohesin-Mutant-Induced Stem
Cell Programs Are Dependent on ERG,
GATA2, and RUNX1
(A) TF expression was determined by qRT-PCR to
determine the knockdown efficiency of two inde-
pendent shRNAs for each of the indicated TFs in
FACS-purified RFP+ CD34-enriched cord blood.
The shRNA exhibiting the strongest knockdown
for each TF was used for subsequent experiments.
(B) CD34-enriched cord blood HSPCs were
double transduced with lentiviruses encoding
scramble or TF-targeting shRNAs (RFP+, from A)
and cohesin WT or mutants (GFP+). 6 days later,
cells were analyzed for RFP and GFP expression
by flow cytometry and representative plots are
presented.
(C) HSPCs isolated and lentivirally transduced as
in (B) were cultured in HSPC retention medium as
in Figure 2. 6 days later, cells were analyzed for
expression of progenitor markers CD34 andCD38.
Representative FACS plots are shown. Key com-
parisons highlighting ERG, GATA2, and RUNX1
knockdown in the setting of mutant RAD21 or
SMC1A are indicated in red boxes.
(D) Summary of data from three independent ex-
periments as described in (C); the percentage of
CD34+ cells was normalized to scramble shRNA
only control. Unpaired Student’s t test was used to
determine statistical significance between cohesin
WT and mutant populations. **p < 0.01.
(E) Schematic model: mutant cohesin impairs he-
matopoietic differentiation and enforces stem cell
programs through the modulation of ERG, GATA2,
and RUNX1 chromatin accessibility, expression,
and activity.mutant expression completely prevented this increase in CD34-
expressing cells (Figures 7C and 7D). These results are consis-
tent with our proposed model that mutant cohesin impairs
hematopoietic differentiation and enforces stem cell programs
through the modulation of ERG, GATA2, and RUNX1 chromatin
accessibility, expression, and activity (Figure 7E).
DISCUSSION
Recurrent mutations in the components of the cohesin complex
have been identified in human AML and other myeloid malig-684 Cell Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Inc.nancies and in particular have been
shown to occur as pre-leukemic muta-
tions in HSCs. Here, we sought to investi-
gate the effects of mutant cohesin
on hematopoiesis, including HSPCs.
Introduction of mutant cohesin into AML
cell lines and primary cord blood HSPC
resulted in a differentiation block with
an increased frequency of CD34+ cord
blood progenitor cells. A similar pheno-
type was observed with knockdown of
RAD21 both in vitro and in vivo, indicating
that mutant cohesin can act through
either haploinsufficiency or dominant-negative mechanisms. Mutant cohesin increased the serial re-
plating ability of human HSPCs in vitro and showed enrichment
for HSCs and leukemia stem cell gene expression programs,
indicating an effect to enforce stem cell functions. Interestingly,
the effect of mutant cohesin was found to be cell context depen-
dent, in that these phenotypes could only be observed in the
most immature HSPC populations. Using ATAC-seq, we deter-
mined that mutant cohesin lead to a state of elevated chromatin
accessibility and higher predicted binding at TF binding sites
for ERG, GATA2, and RUNX1. Moreover, using ChIP-seq, we
formally demonstrated increased binding of GATA2 and
RUNX1 to these sites. Finally, we demonstrated that knockdown
of these three TFs in human HSPCs can revert the differentiation
block induced bymutant cohesin. These results support a model
in which mutant cohesin impairs hematopoietic differentiation
and enforces stem cell programs through the modulation of
ERG, GATA2, and RUNX1 chromatin accessibility, expression,
and activity (Figure 7E).
Our results indicate a link between the role of cohesin in the
regulation of transcription through the modulation of chromatin
accessibility and the maintenance of stem cell functions in
HSPCs. Consistent with a previous report (Yan et al., 2013), we
observed a global loss of open chromatin in cohesion-mutant-
expressing cells, but an increase in accessibility at specific mo-
tifs for key hematopoietic TFs ERG, GATA2, and RUNX1 that in
turn execute stem cell transcriptional programs and phenotypes.
Several mechanisms are possible to explain these results. One
model proposes that the global loss of open chromatin observed
in cohesion-mutant-expressing cells enriches, either directly or
indirectly, for the activity of pioneer factors that can bind chro-
matin in the absence of cohesin. Previous reports have sug-
gested that GATA2 (Wang et al., 2007), RUNX1 (Lichtinger
et al., 2012), and ERG (Chen et al., 2013b) can all function as
pioneer factors in hematopoietic cells. This results in the enrich-
ment of open motifs for these factors and a higher likelihood of
occupancy in cohesion-mutant-expressing cells as detected
here by ATAC-seq andChIP-seq, with a decrease in accessibility
for motifs of non-pioneer factors that promote hematopoietic dif-
ferentiation. The result is impaired hematopoietic differentiation
and enforcement of stem cell programs in HSPCs.
Another possibility is based on the role of cohesin in maintain-
ing chromosome structure along with CTCF. Recent cohesin
ChIA-PET studies in mouse ESCs have shown that many cell
identity genes, including GATA2, are found within chromosome
structures that are formed by the looping of two interacting
CTCF sites co-occupied by cohesin (Dowen et al., 2014). These
looped structures form insulated neighborhoods whose integrity
is important for proper expression of local genes, and it has been
suggested that loss of cohesin would lead to de-repression of
these genes.
We examined the effect of cohesin mutants on hematopoietic
differentiation in isolated subpopulations of human HSPCs and
found that mutant cohesin imparts its differentiation block only
in the most immature HSCs and MPPs. This cell context depen-
dence may derive from the models discussed above in which
cohesin is required to establish accessible chromatin for he-
matopoietic differentiation. However, once the differentiation
program has been established, for example in GMPs for myeloid
differentiation, cohesin is not required to maintain it, and loss of
cohesin function does not revert these cells to a stem cell-like
state or impair differentiation. This may explain our results
demonstrating that cohesin mutations are often detected in
pre-leukemic HSCs in human AML, as they must be acquired
in HSCs to exert their leukemia-promoting effects (Corces-Zim-
merman et al., 2014; Jan et al., 2012).
Our studies of pre-leukemic HSCs in AML demonstrated that
pre-leukemic mutations preferentially occur in genes involved
in regulating the epigenome including DNA methylation
(DNMT3A, TET2, and IDH1/2), histone modifications (ASXL1),
and cohesin (Corces-Zimmerman et al., 2014). A number ofCellstudies investigating the effects of these mutations on hemato-
poietic functions have demonstrated similar phenotypes with
impaired differentiation and maintenance of stem cell programs,
as reported here for cohesin mutations (Challen et al., 2012;
Moran-Crusio et al., 2011; Sasaki et al., 2012). Moreover, we
observed skewed differentiation toward the myeloid lineage
both in vitro and in vivo, as was also detected with TET2 (Pronier
et al., 2011) and IDH1/2 mutations (Chen et al., 2013a; Sasaki
et al., 2012). Collectively, these studies support our model in
which pre-leukemic mutations occur in genes that regulate the
epigenome resulting in impaired hematopoietic differentiation
and enforcement of stem cell programs, followed by down-
stream mutations in drivers of cell proliferation (FLT3 and
RAS), to eventually result in AML (Corces-Zimmerman and
Majeti, 2014).
Interestingly, cohesin mutations have been identified in multi-
ple cancer types, including Ewing sarcoma (Solomon et al.,
2011), colorectal carcinoma (Barber et al., 2008), and bladder
carcinoma (Balba´s-Martı´nez et al., 2013; Solomon et al., 2013).
Conflicting reports (Balba´s-Martı´nez et al., 2013; Solomon
et al., 2011) have reported that cohesin mutations may or may
not be associated with aneuploidy in bladder cancer, implicating
defects in its canonical role inmaintaining sister chromatid cohe-
sion during mitosis as a mechanism for malignant transforma-
tion. Notably, in most AML cases, cohesin mutations are not
associated with karyotypic abnormalities (Cancer Genome Atlas
Research Network, 2013), suggesting that defects in chromatid
cohesion do not contribute to leukemogenesis. Ultimately, it
will be important to determine if cohesin mutations impart the
same phenotype observed in hematopoietic cells in these other
tissues and cellular contexts.
Cohesin mutants impair hematopoietic differentiation and
enforce stem cell programs in primary human HSPCs, and they
occur as pre-leukemic and early mutations in human AML
and myeloid malignancies. These observations indicate that
cohesin mutants are excellent targets for novel therapeutics
with the potential to change disease outcomes. Understanding
the mechanisms by which these mutants act will be critical to
the identification and design of such novel targeted agents,
but the observation here that the effect of cohesin mutants on
impaired hematopoietic differentiation is reversible suggests
that it may be possible and beneficial to target mutant cohesin
in AML and other myeloid malignancies.
EXPERIMENTAL PROCEDURES
AML Cell Lines
THP-1 and TF-1 cells were acquired from ATCC. THP-1 cells were cultured in
RPMI-1640 medium (Life Technologies) with 10% Tet-approved FBS (Clon-
tech) and PenStrep (Life Technologies). TF-1 cells were cultured in the same
medium supplemented with GM-CSF (Peprotech) at 2 ng/ml.
Primary Human Samples
Human AML samples were obtained from patients at the Stanford Medical
Center with informed consent, according to Institutional Review Board (IRB)-
approved protocols (Stanford IRB no. 18329 and no. 6453). Individual case in-
formation is presented in Table S1. Cord blood samples were obtained from
patients at the Lucile Packard Children’s Hospital with informed consent, ac-
cording to IRB-approved protocols (Stanford IRB no. 5637) and fromNewYork
Blood Center. Mononuclear cells from each sample were isolated by Ficoll (GE
Healthcare Dharmacon) separation and cryopreserved in liquid nitrogen.Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier Inc. 685
Lentivirus Transduction
TF-1 and THP-1 cell lines were transduced as previously described (Chan
et al., 2015). Primary humanCD34-enriched cord bloodwas transduced as fol-
lows: wells in a 96-well non-tissue-culture-treated plate were coated with
100 ml of RetroNectin per well (Clontech Laboratories) at 100 mg/ml in PBS
for 2 hr at room temperature (RT). The wells were then blocked with 150 ml
of a 2% (w/v) solution of BSA in PBS for 30 min at RT. The BSA solution was
then aspirated, and lentiviral particles in HBSSwith 25mMHEPESwere added
to each well at a volume of 80–200 ml. The plate was then centrifuged at 3,700
r.p.m. for 2 hr at RT. After the supernatant was aspirated, 1,000–200,000 cells
were added to each well in 150–200 ml of medium. The plate was centrifuged
again at 1,300 r.p.m. for 10 min at RT and then transferred to a 37C incubator
to initiate lentiviral infection.
Generation of Inducible Cell Lines
TF-1 and THP-1 cells were transduced with lentiviral particles made using
the DOX-inducible pINDUCER21 vector modified to express either WT or
mutant cohesin along with constitutive expression of an eGFP marker. The
cells were then sorted for eGFP expression using a FACSAria II (Becton Dick-
inson). Approximate heterozygous gene expression was induced with DOX at
2 mg/ml and replenished every 48 hr.
TF-1 EPO Differentiation Assay
TF-1 cells were induced with DOX for 48 hr and then differentiation was
inducedwith EPO as previously described (Wang et al., 2013). Surface expres-
sion of GPA was analyzed using anti-human GPA-PE (CD235a) (HIR2, BD
Biosciences). Expression of HBG1/2 and KLF-1 was analyzed by qRT-PCR.
For the DOX washout experiment, cells were washed five times in PBS and
then resuspended inmedium supplemented with EPO for an additional 4 days.
The cells were then analyzed for surface expression of GPA and expression of
HBG1/2 and KLF-1 as described above.
HSPC Differentiation Assays
Primary human CD34-enriched cord blood was transduced with lentivirus
(pLVX EF1a-IRES-zsGreen; Clontech) overnight and sorted for GFP expres-
sion using a FACSAria II (Becton Dickinson). For progenitor media assay, cells
were washed and incubated in HPGM medium (Lonza) supplemented with
FLT3L, thrombopoietin, and stem cell factor (SCF). The cytokines were all
purchased from Peprotech and used at 20 ng/ml. 6 days post-culture, differ-
entiation of GFP+ cells was assessed by flow cytometry using anti-human
CD34-APC (8G12) and CD38-PE-Cy7 (HB7) (BD Biosciences). For the myeloid
differentiation assay, cells were cultured in Myelocult H5100 (Stem Cell Tech-
nologies) with 20 mg/ml each of IL-3, SCF, FLT3L, and GM-CSF (Peprotech) for
6 days. Myeloid differentiation was assessed by flow cytometry using anti-
human CD33-PE (WM53) and CD14-APC-Cy7 (MfP9) (BD Biosciences). For
the erythroid differentiation assay, cells were cultured in Stemspan II with
erythroid expansion kit (StemCell Technologies, Inc.) for 6 days. Erythroid
differentiation was assessed by flow cytometry using anti-human GPA-PE
(CD235a) (HIR2) and CD71-PE-Cy7 (OKT9) (BD Biosciences).
Human Xenografts and Assessment of Human Engraftment in NSG
Mice
Transplantation of cord blood cells into NSG mice and engraftment of human
cells within mouse bone marrow was assessed by immunophenotyping as
previously described (Chan et al., 2015).
Methylcellulose Colony Assays
HSPCs were lentivirally transduced and isolated as described above (see
HSPC Differentiation Assays) and then cultured for 14 days in Methocult
H4435 Enriched methylcellulose (Stem Cell Technologies) according to stan-
dard protocols. For replating, methylcellulose was dissolved with the addition
of DMEMat RT, and 1,000-10,000 cells were counted and replated in the same
medium.
Expression Microarray Analysis
RNA was extracted from GFP+ sorted HSPC-enriched cord blood that was
transduced with control vector (pLVX-IRES-zs-GREEN), cohesin WT, or cohe-
sin mutant vectors. RNA was processed and analyzed using the Human686 Cell Stem Cell 17, 675–688, December 3, 2015 ª2015 Elsevier InGenome U133 Plus 2.0 Array (Affymetrix) according to the manufacturer’s
protocol. Array data are deposited in Gene Expression Omnibus database
(accession number GEO: GSE73224).
For data analysis, CEL files were analyzed using GenePattern (Broad
Institute) according to current protocols. Pearson correlation values were
determined from all genes that passed normalization and filters. Gene Set
Enrichment Analysis (GSEA) was conducted according to current protocols.
ChIP-Seq
ChIP-seq was performed as described previously (Calo et al., 2015). Briefly,
TF-1 RAD21 Q592* and TF-1 RAD21 WT cells were induced with DOX for
6 days, after which 100,000,000 cells were crosslinked in 1% formaldehyde
for 10 min at RT. Typically, 5 million cells were used for each ChIP experiment
and chromatin was sheared on a Bioruptor (Diagenode) to an average of 200–
400 bp. After specific recovery of chromatin-bound proteins via immunopre-
cipitation, samples were reverse crosslinked at 65C overnight and DNA
was purified for subsequent library preparation. ChIP-seq libraries were pre-
pared according to the NEBNext protocol and sequenced using Illumina
NextSeq. The following antibodies were used for ChIP studies: SMC3 (clone:
ab9263, Abcam), GATA2 (clone: sc-9008, Santa Cruz Biotechnology), and
RUNX1 (clone: sc-365644, Santa Cruz Biotechnology). Sequencing data are
deposited in GEO database (accession number GEO: GSE73207).
ATAC-Seq
TF-1 RAD21 Q592* and TF-1 RAD21 WT were induced with DOX for 6 days,
and then 50,000 cells were directly transposed as previously described (Buen-
rostro et al., 2013). Cord blood HSPCs were transduced with control vector,
cohesin WT, or cohesin mutant vectors and sorted after 3 days for GFP+ cells.
Sorted cells (ranging from 1,000–20,000) were immediately transposed as pre-
viously described (Buenrostro et al., 2013). Sequencing data are deposited in
GEO database (accession number GEO: GSE73206).
Statistical Analysis
Unless otherwise stated, p values comparing two means were calculated
using the two-tailed unpaired Student’s t test in Prism version 6 (GraphPad
Software, Inc.). p < 0.05 was considered statistically significant. All bar graphs
show mean with ± SEM.
ACCESSION NUMBERS
The accession number for the microarray studies reported in this paper is
GSE73224; for the ATAC-Seq studies, it is GEO: GSE73206; and for the
ChIP-Seq studies, it is GEO: GSE73207.
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